AbbVie's VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) Receives Approval in Japan for the Treatment of Genotype 1 Chronic Hepatitis C
New interferon and ribavirin-free treatment option for patients with most common type of hepatitis in Japan, genotype 1 chronic hepatitis C, including those with compensated cirrhosis VIEKIRAX consists of a 12-week, two direct-acting antiviral, fixed... Biopharmaceuticals, RegulatoryAbbVie, VIEKIRAX, ombitasvir, paritaprevir, ritonavir
CONCLUSIONS: An expanded CLD definition and alcohol-attributable fractions can be used to create comprehensive data on CLD mortality. When stratified by CLD cause and demographic characteristics, these data may help states and jurisdictions improve CLD prevention programs. PMID: 29664698 [PubMed - as supplied by publisher]
Conclusions: SMV/SOF or DCV/SOF combinations are safe and highly effective in HCV-GT4 treatment. Cirrhosis and failure of prior interferon-based treatment did not influence treatment response.
Conclusion: PrOD regimen demonstrated an excellent efficacy and good tolerability. Both prospective adjustment of concomitant medication and further on-treatment adjustment allowed for a safe treatment course.Kidney Blood Press Res 2018;43:594 –605
ConclusionTreatment with SOF (400 mg) plus DCV (60 mg), with or without RBV (800–1000 mg) for 12 or 24 weeks, was effective and well tolerated in chronic hepatitis C genotype 4 patients. SVR rates were higher for patients with no cirrhosis. Addition of RBV has benefit only in treatment-experienced group receiving 24 weeks.
Exclusive: 71 million people stand to benefit from reduced price treatment for virus which can lead to liver cirrhosis, cancer and deathAn affordable hepatitis C treatment has been shown to be safe and effective, with very high cure rates for patients including hard-to-treat cases, in interim clinical trial results that offer hope to the 71 million people living with the disease worldwide. The treatment is expected to cost $300 for 12 weeks, or $3.50 per day, in Malaysia, where trials were conducted along with Thailand – a fraction of the cost of other hepatitis C medicines produced by major drugmakers, which often r...
(European Association for the Study of the Liver) A program of decentralized public healthcare achieves high rates of cure regardless of genotype or the presence of cirrhosis: the Punjab Model.
(European Association for the Study of the Liver) A Canadian study suggests that biannual or annual ultrasound screening for HCC is likely to be cost effective after a sustained virological response in those with hepatitis C-related cirrhosis, but not in those with advanced fibrosis without cirrhosis.
Studies have produced conflicting results of the incidence of hepatocellular carcinoma (HCC) in patients with in hepatitis C virus (HCV)-associated cirrhosis treated with direct-acting antivirals (DAAs). Data from clinics are needed to accurately assess the occurrence rate of HCC in patients with cirrhosis in the real world.
The natural course of chronic hepatitis C (CHC) varies widely among individuals , and the early recognition of patients at risk for developing liver fibrosis and cirrhosis is essential to take preventive measures that may affect the course of CHC . Several risk factors have been associated with liver fibrosis progression, including age at infection, sex, route of infection, HCV genotype, and obesity among others . In this regard, single nucleotide polymorphisms have been also associated with liver disease progression [3,4].